Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Increase in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 141,200 shares, a growth of 27.7% from the December 15th total of 110,600 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average trading volume of 95,500 shares, the days-to-cover ratio is presently 1.5 days.

Aileron Therapeutics Stock Performance

The firm has a 50-day moving average price of $2.52 and a 200-day moving average price of $2.80. The company has a market capitalization of $45.72 million, a PE ratio of -0.68 and a beta of 2.24. Aileron Therapeutics has a 1-year low of $1.61 and a 1-year high of $7.42.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALRN. KG&L Capital Management LLC bought a new stake in shares of Aileron Therapeutics during the third quarter worth approximately $46,000. Sigma Planning Corp grew its holdings in Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after acquiring an additional 86,185 shares during the period. Geode Capital Management LLC raised its position in shares of Aileron Therapeutics by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock valued at $814,000 after acquiring an additional 59,370 shares during the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Aileron Therapeutics by 82.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after purchasing an additional 209,367 shares during the period. Finally, University of Texas Texas AM Investment Management Co. bought a new position in shares of Aileron Therapeutics in the 2nd quarter worth $4,925,000. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).